Patents by Inventor Guiyuan Lei

Guiyuan Lei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250177414
    Abstract: Provided are a combination therapy comprising inavolisib, palbociclib and fulvestrant and methods of treating PIC3CA-mutant, hormone receptor positive (HR+) and HER2 negative (HER2?) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib, palbociclib and fulvestrant. The combination therapy produces a statistically significant and clinically meaningful improvement to the patient as compared to administering palbociclib and fulvestrant alone to a comparable patient.
    Type: Application
    Filed: December 3, 2024
    Publication date: June 5, 2025
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc., Pfizer Inc.
    Inventors: Eirini Thanopoulou, Yanling Jin, Guiyuan Lei, Colin James Neate, Noopur Shankar, Chunyan Song, Thomas James Stout
  • Publication number: 20120009177
    Abstract: This invention provides methods, compositions, and kits relating to gene product biomarkers where gene expression levels are correlated with therapeutic response of rheumatoid arthritis patients to treatment with an IL-6 receptor antagonist, such as an IL6-R antibody. The methods, compositions, and kits of the invention can be used to identify rheumatoid arthritis patients who are likely, or not likely, to respond to IL-6 receptor antagonist treatments.
    Type: Application
    Filed: June 6, 2011
    Publication date: January 12, 2012
    Applicant: Roche Molecular Systems, Inc.
    Inventors: Adam Platt, Jianmei Wang, Guiyuan Lei, Laurent Essioux, Wei-min Liu, P. Mickey Williams